16
Participants
Start Date
April 30, 2015
Primary Completion Date
October 31, 2018
Study Completion Date
April 7, 2022
TAA-Specific CTLs
"Patients may be pre-medicated with Benadryl up to 1 mg/kg IV (max 50 mg) and Tylenol 10 mg/kg po (max 650 mg).~Cell Administration: Tumor-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.~Patients with stable disease or better will receive up to 6 further doses of CTLs, as long as they continue to show disease stabilization or improvement by RECIST criteria at their 8 week or subsequent evaluations. Each dose will consist of the same number as their second injection or less (if there is not enough product available for the subject's original dose).~Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion."
Houston Methodist Hospital, Houston
Texas Children's Hospital, Houston
The Methodist Hospital Research Institute
OTHER
Center for Cell and Gene Therapy, Baylor College of Medicine
OTHER
Solving Kids' Cancer
OTHER
Pierce Phillips Charity
UNKNOWN
Baylor College of Medicine
OTHER